Sector Gamma AS Makes New $31.48 Million Investment in Pfizer Inc. (NYSE:PFE)

Sector Gamma AS acquired a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,093,416 shares of the biopharmaceutical company’s stock, valued at approximately $31,479,000. Pfizer accounts for 7.6% of Sector Gamma AS’s holdings, making the stock its 2nd biggest position.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Unique Wealth Strategies LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $1,069,000. Intact Investment Management Inc. lifted its stake in shares of Pfizer by 30.9% in the 4th quarter. Intact Investment Management Inc. now owns 438,800 shares of the biopharmaceutical company’s stock valued at $12,633,000 after purchasing an additional 103,600 shares during the period. Addison Advisors LLC lifted its stake in shares of Pfizer by 11.6% in the 4th quarter. Addison Advisors LLC now owns 9,322 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 970 shares during the period. Gilliland Jeter Wealth Management LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $962,000. Finally, Headlands Technologies LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $1,184,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.14 during mid-day trading on Friday, reaching $25.40. The stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The company has a market cap of $143.83 billion, a P/E ratio of 70.56, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The business’s 50 day moving average price is $26.96 and its 200 day moving average price is $28.42.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the previous year, the business earned $1.14 earnings per share. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.61%. Pfizer’s payout ratio is currently 466.67%.

Analysts Set New Price Targets

A number of research firms have recently commented on PFE. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.